$AMLX News

Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting

Amylyx Pharma Q2 2026 Earnings Call Transcript

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise

Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization

Why Amylyx Pharmaceuticals Stock Skyrocketed Today

AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering

A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial